Nevada · J7324

Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose in Nevada

Nevada Medicare Avg
$98.54
0% above national avg
National Medicare Avg
$98.22
All states combined
Billed Charge (NV)
$478.35
What providers submit
Est. Commercial (NV)
$300.96
National avg: $280.88
Est. Cash / Self-Pay (NV)
$225.60
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

2.1K
Services in NV
43
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Nevada

Provider Medicare Services
Ong, Bernard MD $100.93 905

Nevada Pricing in Context

In Nevada, CPT code J7324 (Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose) carries an average Medicare payment of $98.54 — 0% above the national benchmark of $98.22. 43 providers across the state submitted claims for this procedure in 2023, performing 2.1K total services. Individual payments in NV ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Nevada is $478.35, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Nevada sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in Nevada lands near $300.96, with self-pay cash prices typically around $225.60. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose cost in Nevada?

The average Medicare payment for Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose in Nevada is $98.54, which is 0% above the national average of $98.22. Providers in NV typically bill $478.35 for this procedure.

What does Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose cost with insurance in Nevada?

With commercial insurance in Nevada, Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose costs an estimated $300.96. Without insurance, the estimated cash price is $225.60. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose in Nevada?

43 providers in Nevada billed Medicare for Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose in 2023, performing 2.1K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose cheaper in Nevada than the national average?

No — Hyaluronan Or Derivative, Orthovisc, For Intra-Articular Injection, Per Dose costs 0% above the national average in Nevada. The state average Medicare payment is $98.54 compared to $98.22 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial